On November 10, 2026 CEL-SCI Corporation (NYSE American: CVM) reported that the Company’s Chief Scientific Officer and Multikine (Leukocyte Interleukin, Injection)* inventor and developer, Dr. Eyal Talor, has received his second invitation to deliver a keynote address at an international head and neck cancer conference. Dr. Talor has been invited to speak at the 3 rd Global Congress on Otolaryngology, Head and Neck Surgery which will take place on June 9-10, 2027 in Lisbon, Portugal.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Talor’s presentation, titled "Disease/Tumor Biomarkers Prognosticate Overall Survival Benefit in Oral Squamous Cell Carcinoma: A Novel Neoadjuvant Cancer Immunotherapy" will address findings from CEL-SCI’s Phase 3 study of Multikine and the Company’s work using tumor and disease biomarkers to identify patients most likely to benefit from Multikine treatment before surgery.

This follows Dr. Talor’s recent keynote speech at the 6th World Congress on Otology, Rhinology and Laryngology in Rome on October 26. Both invitations came after recent peer-reviewed publications of CEL-SCI’s IT-MATTERS Phase 3 research. The series of scientific publications and keynote invitations is expanding the visibility of CEL-SCI’s biomarker-based approach among specialists who diagnose and treat head and neck cancer.

"We believe these keynote invitations reflect growing scientific interest in what we have demonstrated with Multikine: the first overall survival advantage for a neoadjuvant treatment in this patient population in many decades, and a biomarker-based method that can identify at diagnosis the patients most likely to achieve this substantial survival benefit," said CEL-SCI CEO Geert Kersten. "This combination is what makes our findings potentially groundbreaking for head and neck cancer patients. We are now applying this patient selection method prospectively in our Registration Study of 212 patients."

CEL-SCI’s completed 928-patient IT-MATTERS Phase 3 study identified disease and tumor biomarkers which can be applied at diagnosis to select previously untreated, locally advanced head and neck cancer patients most likely to benefit from neoadjuvant Multikine administration, a pre-surgery treatment. CEL-SCI is applying these biomarkers prospectively as patient selection criteria in its 212-patient Registration Study, which is designed with approximately 97% statistical power to detect the survival effect previously observed in this population.

Surgeons, healthcare professionals, academic scholars and researchers from around the world are expected to participate in the 3rd Global Congress on Otolaryngology, Head and Neck Surgery in Lisbon. The Congress provides a forum for scientific research, surgical advances and clinical developments in otolaryngology and head and neck surgery. The theme of the 2027 Congress is "Transforming ENT Care through Research, Innovation, and Clinical Excellence."

About Multikine

Multikine is a novel cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated locally advanced head and neck cancer. Its goal is to activate a person’s immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world’s largest locally advanced, resectable head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%. The results of the IT-MATTERS global Phase 3 study represent the first overall survival advantage for a neoadjuvant treatment, in the treatment naïve resectable locally advanced head and neck squamous cell carcinoma (cancer) patients, in many decades.

(Press release, Cel-Sci, NOV 10, 2026, View Source;storyId=4505652807261336 [SID1234674584])